Children and adults in the Netherlands with atypical hemolytic uremic syndrome (aHUS) experience differences in clinical presentation and outcomes despite carrying the same disease-linked genetic variant, according to a new study. Children with this variant presented with more profound blood cell abnormalities but milder kidney impairment than adult patients.
News
Two brothers carrying identical genetic variants associated with atypical hemolytic uremic syndrome (aHUS) and hereditary thrombotic thrombocytopenic purpura (TTP) developed different disease manifestations, as reported in a case series. TTP is a blood disorder, like aHUS, characterized by thrombotic microangiopathy (TMA), in which blood clots form in tiny…
Complement inhibitors helped a woman partially recover from atypical hemolytic uremic syndrome (aHUS) related to pregnancy despite a five-week delay in starting treatment, according to a case report. Symptoms of kidney damage developed during the 29-year-old’s third trimester. As a result, the woman began regular hemodialysis, a procedure that…
People with atypical hemolytic uremic syndrome (aHUS) without a clear genetic cause may have rare mutations in overlooked parts of complement system genes, a new study from Europe suggests. The researchers found that one such mutation in the CFI gene — a known aHUS risk gene — greatly reduced…
A woman with atypical hemolytic uremic syndrome (aHUS) successfully underwent a second kidney transplant as treatment with Soliris (eculizumab) largely prevented or eased the complications that led to failure of her first transplant. The medication has helped stabilize the woman’s kidney function for four years, researchers wrote in a…
A COVID-19 infection apparently triggered the development of atypical hemolytic uremic syndrome (aHUS) in a 75-year-old man who had recently received a kidney transplant, according to a case report. Treatment with Ultomiris (ravulizumab) helped resolve his symptoms, supporting the use of the medication post-kidney transplant. Some kidney transplant…
Recurrent pancreatitis, or inflammation of the pancreas, an organ essential for digestion, may trigger atypical hemolytic uremic syndrome (aHUS) in people with mutations that increase the risk of this immune system-related condition. That’s according to a new report detailing the case of a young boy in India who was…
A man who developed a severe, full-body flare of psoriasis that caused his skin to peel and swell and triggered kidney failure and atypical hemolytic uremic syndrome (aHUS) improved after being treated with corticosteroids, intravenous immunoglobulin, and the complement inhibitor Soliris (eculizumab). “Early recognition of this overlap syndrome…
A previously healthy young man in Greece who later developed atypical hemolytic uremic syndrome (aHUS) improved rapidly after being treated with the complement inhibitor Soliris (eculizumab), which helped his heart function recover over time, but delayed therapy was linked to permanent kidney failure requiring dialysis. “This case emphasizes…
Complement inhibitors and plasma exchange therapy are equally safe and effective for atypical hemolytic uremic syndrome (aHUS), but complement inhibitors like Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) offer an edge in preventing relapses, especially in children, according to a new pooled analysis of real-world data. The analysis reveals…
Recent Posts
- aHUS symptoms differ in children, adults with same C3 variant
- Brothers with shared mutations develop different TMA patterns
- The days surrounding my aHUS diagnosis were a lonely time for me
- Delayed complement inhibition resolves pregnancy-related aHUS
- What comes next: Telling my story after an aHUS diagnosis
- Hidden rare mutations may help explain mystery cases of aHUS
- Soliris enables successful second kidney transplant: Case study
- The struggles of losing weight when you’re chronically ill
- COVID-19 triggers aHUS in man following kidney transplant
- Heart complications were a puzzling part of my aHUS journey